been remunerated. He has attended international conferences with Napp and AstraZeneca and has consultancy agreements with AstraZeneca and Vectura

P26 HOW DOES THE SALFORD LUNG STUDY IN COPD (SLS COPD) PATIENT POPULATION FIT INTO THE GOLD 2017 CLASSIFICATION GRID?

10.1136/thoraxjnl-2017-210983.461

J Vestbo: Honoraria from GSK, AstraZeneca, BI, Chiesi, and Novartis for consulting/presenting

I Boucot: Employment and stock ownership (GSK)

L Frith: Employment and stock ownership (GSK)

N Diar Bakerly: Employing organisation provided IT support to automated data collection method for the SLS COPD trial. NDB received financial support to attend meeting in the form of non-restricting educational grants from GSK, Novartis, Astra Zeneca, and BI

S Collier: Employment and stock ownership (GSK)

DA Leather: Employment and stock ownership (GSK)

JM Gibson: Employing organisation provided IT support for automated data capture collected during SLS COPD

A Woodcock: Honoraria from GSK, Chiesi and Zambon

P27 DEPRIVATION IN THE COPD SALFORD LUNG STUDY (SLS) IS ASSOCIATED WITH HIGHER HEALTHCARE COSTS BUT DOES NOT MODERATE THE MAIN OUTCOMES

10.1136/thoraxjnl-2017-210983.462

R Jones: Personal fees from AstraZeneca, Boehringer-Ingelheim, Chiesi, Cipla, GSK, Novartis and Pfizer

A Nicholls: GSK employee, holds GSK shares

D Browning: GSK employee

N Diar Bakerly: Employing organisation provided IT support to automated data collection method for the SLS COPD and Asthma trials. NDB received financial support to attend meeting in the form of non-restricting educational grants from GSK, Novartis, Astra Zeneca and BI

A Woodcock: Honoraria (GSK, Chiesi and Zambon)

J Vestbo: Honoraria from GSK, AstraZeneca, BI, Chiesi and Novartis for consulting/presenting

D Leather: GSK employee, holds GSK shares

P63 ESTABLISHING THE COST OF HOSPITALISED COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE UK: A HOSPITAL EPISODE STATISTICS (HES) ANALYSIS

10.1136/thoraxjnl-2017-210983.463

This research was sponsored by Pfizer.

J Campling, D Jones, G Ellsbury, C Czudek, and H Madhava are employees of Pfizer and have no conflicts of interest to declare.

M Slack has received personal fees from GSK, Pfizer, AstraZeneca and Sanofi Pasteur as a speaker at international

meetings and as a member of advisory boards (outside the scope of the submitted work). She has also worked as a contractor for Pfizer. HES analyses were done by Harvey Walsh Health Informatics, and medical writing support was provided by Richard Watt at Sudler, both of which were funded by Pfizer.

P69 FUNCTIONALITY, RELIABILITY, AND PERFORMANCE OF AN ACCESSORIZED PRE-FILLED SYRINGE WITH HOME-ADMINISTERED SUBCUTANEOUS BENRALIZUMAB FOR ADULT PATIENTS WITH SEVERE ASTHMA

10.1136/thoraxjnl-2017-210983.464

AH Mansur: Received speaker fees and payment (including gifts or other consideration or 'in kind' compensation) through attending advisory board meeting to various companies including Novartis, Roche, AstraZeneca, NAPP, BI; Received educational grants for service development from Novartis pharmaceuticals; Participated in Phase IIb and III clinical trials with AstraZeneca, Novartis, Roche

GT Ferguson: Received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Pearl Therapeutics; Served on board or advisory committee for AstraZeneca, Pearl Therapeutics, and Novartis; Received research support from AstraZeneca, Boehringer Ingelheim, Pearl Therapeutics, Sunovion, Novartis, and Theravance

JS Jacobs: Speaker/Teacher for Shire, Teva; Clinical Investigator for CSL Behring, Genentech, Regeneron, Sanofi, Shire, and Teva; Acted on Advisory committee for CSL Behring, Pharming Group, and Regeneron; Served as Independent Contractor for Genentech, CSL Behring, Regeneron, and Teva

J Hebert: Consultant: Novartis, Merck, Teva, CSL Behring, Baxter, Shire; Conference Speaker: Merck, Novartis, Shire, Meda, CSL Behring; Investigator in clinical trials: Merck, Novartis, Stallergen, GSK, Boehringer Ingelheim, CSL Behring, DBV

C Clawson: Employee of MedImmune; Holds stock in AstraZeneca

W Tao: Employee of AstraZeneca

Y Wu: Employee of AstraZeneca

M Goldman: Employee of AstraZeneca

P198 FENO AND BLOOD EOSINOPHILS AS BIOMARKERS IN PREDICTING ASTHMA EXACERBATIONS

10.1136/thoraxjnl-2017-210983.465

S Rastogi: Employee of AstraZeneca

S Bosnic-Anticevich: Consultancy/lectures/advisory panels: AstraZeneca, GSK, TEVA, Boehringer Ingelheim, MEDA/MYLAN/Mundipharma

I Pavord: Speaker's honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, and GSK. He has received honoraria for attending advisory panels with Almirall, Genentech, Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, MSD, Schering-Plough, Novartis, Dey, Napp and Respivert. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca and Napp.

N Roche: Grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3M, personal fees from Zambon, outside the submitted work

D Halpin: Personal fees and non-financial support from Boehringer Ingelheim, personal fees from GSK, personal fees from AstraZeneca, personal fees from Pfizer, personal fees and non-financial support from Novartis, personal fees from Chiesi Pharmaceuticals & personal fees from Sandoz.

OS Usmani: Industry-academic funding from Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, Mundipharma International, and has received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Novartis, Mundipharma International, Pearl Therapeutics, Roche, Sandoz, Takeda, UCB, Vectura and Zentiva.

G Brusselle: Honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis, Pfizer and UCB; he is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis.

S Wan Yau Ming: Employee of OPRI; OPRI did the analyses under contract and with funding from AstraZeneca.

S Halim: Employee of AstraZeneca

G Gopalan: Employee of AstraZeneca

D Price: Board Membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore; and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment.

P254

FEASIBILITY OF ULTRASHORT ECHO TIME (UTE) MRI TO EVALUATE THE EFFECT OF LUMACAFTOR/IVACAFTOR THERAPY IN CHILDREN WITH CYSTIC FIBROSIS (CF) HOMOZYGOUS FOR F508DEL

10.1136/thoraxjnl-2017-210983.466

S Nagle reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study; non-financial support from GE Healthcare (institution/department support).

AS Brody reports personal fees from Vertex Pharmaceuticals during the conduct of the study.

J Woods reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study.

KM Johnson reports personal consulting fees Vertex Pharmaceuticals during the conduct of the study.

L Wang, G Marigowda, D Waltz, C Hug are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

J Goldin reports 'other' conflicts – Founder of MedQIA during the conduct of the study.

F Ratjen reports grants and personal fees from Vertex Pharmaceuticals, personal consulting fees from Novartis, Bayer, Roche, Genetech, and Prosteostasis.

P255

RATE OF LUNG FUNCTION DECLINE IN PATIENTS WITH CYSTIC FIBROSIS (CF) HAVING A RESIDUAL FUNCTION GENE MUTATION

10.1136/thoraxjnl-2017-210983.467

G Sawicki reports personal fees from Vertex Pharmaceuticals outside the submitted work. (advisory boards)

MW Konstan, E McKone, RB Moss reports personal consulting fees from Vertex Pharmaceuticals and institutional grant funding from Vertex Pharmaceuticals during the conduct of the study.

B Lubarsky and E Suthoff are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

S Millar and D Pasta are employees of ICON Clinical Research, which was paid by Vertex Pharmaceuticals for providing analytical services on this project and which is paid by various pharmaceutical, biotechnology, and device companies for providing clinical research services.

N Mayer-Hamblett and CH Goss report institutional grant funding from Vertex Pharmaceuticals during the conduct of the study.

W Morgan reports grants from NIH/NHLBI, grants from NIH/NIAID, grants from Cystic Fibrosis Foundation, personal fees from Cystic Fibrosis Foundation, personal fees from University of Arizona, personal fees from American College of Chest Physicians, personal fees from American Thoracic Society, personal fees from Elsevier outside the submitted work.